{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:50:57Z","timestamp":1776923457673,"version":"3.51.2"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acinar adenocarcinoma is the most common subtype of prostate cancer, while primary prostatic urothelial carcinoma is clinically rare. The composite tumor with both occurring simultaneously within the prostate is even rarer, with limited clinical reports and diagnostic and therapeutic experience available to date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      This article reports a case of a 75-year-old male with concurrent prostatic acinar adenocarcinoma and primary prostatic urothelial carcinoma. The patient was admitted to the hospital due to an elevated prostate-specific antigen (PSA) level detected during physical examination for 2\u202fyears. Preoperative magnetic resonance imaging (MRI) showed a nodule in the left peripheral zone of the prostate, and radical prostatectomy was performed subsequently. Postoperative pathological diagnosis revealed prostatic acinar adenocarcinoma (Gleason score 4\u202f+\u202f3, pT3b stage) and primary prostatic urothelial carcinoma\n                      <jats:italic>in situ<\/jats:italic>\n                      with microinvasion (&amp;lt;0.1\u202fcm). The patient received disitamab vedotin targeted therapy 6\u202fmonths after surgery, and multi-point biopsy of the bladder mucosa 10\u202fmonths after surgery showed no tumor tissue. At the time of this report, the patient had undergone 15\u202fmonths of follow-up with no evidence of tumor recurrence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The composite tumor of concurrent prostatic acinar adenocarcinoma and primary prostatic urothelial carcinoma is clinically rare. Definitive diagnosis requires comprehensive judgment based on imaging examinations, histopathological observation and immunohistochemical detection. Individualized treatment plans should be formulated based on multidisciplinary consultation, and long-term close follow-up of patients is necessary to monitor tumor recurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1830418","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:31:22Z","timestamp":1776922282000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A rare case of concurrent prostatic acinar adenocarcinoma and primary prostatic urothelial carcinoma: case report and literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Yan","family":"Xia","sequence":"first","affiliation":[{"name":"Cancer Center, Department of Pathology, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yamei","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Urology, Hangzhou Hospital of Traditional Chinese Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.urolonc.2007.12.010","article-title":"Dilemmas in the treatment of urothelial cancers of the prostate","volume":"27","author":"Walsh","year":"2009","journal-title":"Urol Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1177\/0041536219845678","article-title":"Metastatic primary urothelial carcinoma of the prostatic urethra: a case report","volume":"86","author":"Kisa","year":"2019","journal-title":"Urologia"},{"key":"ref3","volume-title":"WHO Classification of Tumours: Urinary and male genital Tumours","author":"Epstein","year":"2022"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"106059","DOI":"10.1016\/j.humpath.2026.106059","article-title":"Prostatic adenocarcinoma identified on transurethral resection of bladder tumor: a clinicopathologic series of a diagnostically relevant potential pitfall","volume":"171","author":"Wu","year":"2026","journal-title":"Hum Pathol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/10668969221105624","article-title":"A rare case of co-existing mucin-producing urothelial-type adenocarcinoma of the prostate and acinar adenocarcinoma","volume":"31","author":"Nova-Camacho","year":"2023","journal-title":"Int J Surg Pathol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"5952","DOI":"10.12998\/wjcc.v12.i26.5952","article-title":"Synchronous prostatic acinar adenocarcinoma and primary prostatic urothelial carcinoma: a case report and literature review","volume":"12","author":"Wang","year":"2024","journal-title":"World J Clin Cases"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4103\/UA.UA_97_17","article-title":"Synchronous primary adenocarcinoma and urothelial carcinoma of prostate: a rare case report","volume":"9","author":"Sharma","year":"2017","journal-title":"Urol Ann"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/RLU.0000000000003136","article-title":"Ureteral metastasis from prostate cancer: a PSMA PET pitfall","volume":"45","author":"Chauss\u00e9","year":"2020","journal-title":"Clin Nucl Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3332\/ecancer.2025.2022","article-title":"Primary urothelial carcinoma of the prostate: report of two cases and review of the literature","volume":"19","author":"Nicol\u00e1s","year":"2025","journal-title":"Ecancermedicalscience"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/00129039-200209000-00008","article-title":"Prostatic adenocarcinoma with urothelial (transitional cell) carcinoma features","volume":"10","author":"Mai","year":"2002","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"E353","DOI":"10.5489\/cuaj.1532","article-title":"Synchronous primary malignancies of the male urogenital tract","volume":"8","author":"Qarro","year":"2014","journal-title":"Can Urol Assoc J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5534\/wjmh.180040","article-title":"Role of androgen receptor in prostate cancer: a review","volume":"37","author":"Fujita","year":"2019","journal-title":"World J Mens Health"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.mce.2017.06.021","article-title":"Role of the androgen receptor in urothelial cancer","volume":"465","author":"Inoue","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jvir.2022.02.010","article-title":"Closing the gaps in racial disparities in critical limb ischemia outcome and amputation rates: proceedings from a society of interventional radiology foundation research consensus panel","volume":"33","author":"Bryce","year":"2022","journal-title":"J Vasc Interv Radiol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30431-5","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1830418\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:31:23Z","timestamp":1776922283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1830418\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":17,"alternative-id":["10.3389\/fmed.2026.1830418"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1830418","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"article-number":"1830418"}}